Gastrointestinal toxicities from targeted therapies: measurement, duration and impact

Area of Science:

• Oncology
• Clinical Pharmacology
• Patient-Reported Outcomes

Background:

• Gastrointestinal toxicities are significant adverse events associated with targeted cancer therapies.
• These toxicities can compromise patient quality of life, treatment adherence, and overall outcomes.
• Current assessment methods for these toxicities may have limitations affecting trial results.

Purpose of the Study:

• To review methodological challenges in assessing gastrointestinal toxicities from targeted therapies.
• To examine the impact of measurement methods, toxicity duration, and treatment program integration.
• To highlight areas for improvement in clinical trial design and adverse event evaluation.

Main Methods:

• Literature review focusing on the assessment of gastrointestinal toxicities in targeted therapy trials.
• Analysis of reporting modalities (physician vs. patient) and their accuracy.
• Discussion of factors influencing treatment adherence related to toxicity.

Main Results:

• Physician-reported adverse events are generally less accurate than patient-reported outcomes for gastrointestinal toxicities.
• Integration of both physician and patient reporting is recommended for comprehensive toxicity assessment.
• Underreporting of lower-grade toxicities and symptom duration is common in clinical trials.

Conclusions:

• Methodological considerations in adverse event assessment are critical for targeted therapy trials.
• Refining toxicity assessment strategies, particularly for gastrointestinal effects, is essential.
• Improved methods can lead to better patient management and treatment efficacy.